Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS: Everolimus as Adjuvant Therapy for LAR Breast Cancer
NCT07407517Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2026
- Primary completion
- Feb 2033
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of everolimus in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07407517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407517.